Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, or Von Hippel-Lindau Disease-Associated Tumors
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET) or von Hippel-Lindau (VHL) Disease-Associated Tumors. The primary